You searched for: raptivabehandling (Svenska - Engelska)

pneumokockvaccination 6 veckor efter avslutad raptivabehandling gav normalt resultat.
a pneumococcal vaccine administered 6 weeks after discontinuation of raptiva yielded normal results.

patienter bör inte ta levande eller levande försvagade vacciner under raptivabehandling.
patients should not receive live and live-attenuated vaccines during raptiva treatment.

fall efter avslutad behandling inträffade både hos patienter som svarade och som inte svarade på raptivabehandling.
cases occurring after discontinuation were observed both in patients responding or not responding to raptiva treatment.

i en studie om 66 patienter med måttlig plack psoriasis undersöktes immunoresponsen under och efter raptivabehandling.
in a study of 66 patients with moderate plaque psoriasis, immune responses during and after raptiva treatment were investigated.

i stora placebokontrollerade kliniska studier och i långtidsstudier utvecklade mellan 40 och 50 procent av patienterna ihållande asymtomatisk lymfocytos under raptivabehandling.
leucocytosis and lymphocytosis: in large placebo-controlled and in long-term clinical studies, between 40 and 50% of patients developed sustained asymptomatic lymphocytosis during raptiva therapy.

efter 35 dagars raptivabehandling var andelen patienter behandlade med efalizumab och med positivt svar på hudtest mot candida signifikant lägre jämfört med placebogruppen.
after 35 days of treatment with raptiva, the proportion of subjects treated with efalizumab with positive skin test reactions to candida was significantly reduced compared with the placebo group.

patienter bör inte ta levande eller levande försvagade vacciner under raptivabehandling. (se avsnitt 4.4).
patients should not receive live and live-attenuated vaccines during raptiva treatment. (see section 4.4).

primära vaccinationer under raptivabehandling kan ge lägre antikroppsnivåer än de som observerats hos icke- behandlade patienter men den kliniska signifikansen av detta är okänd.
neo-vaccinations given during treatment with raptiva may induce antibody levels lower than non-treated subjects, but the clinical significance of this is unknown.

antikroppssvaret mot en experimentell ny antigen (∅x174) minskade under behandling med raptiva men började normaliseras 6 veckor efter avslutad raptivabehandling och uppvisade ingen toleransutveckling.
antibody response to an experimental neo-antigen (∅ x174) was reduced during raptiva therapy, but began to normalize 6 weeks after discontinuation of raptiva therapy and did not demonstrate tolerance induction.

antikroppssvaret mot en experimentell ny antigen (x174) minskade under behandling med raptiva men började normaliseras 6 veckor efter avslutad raptivabehandling och uppvisade ingen toleransutveckling.
antibody response to an experimental neo-antigen (x174) was reduced during raptiva therapy, but began to normalize 6 weeks after discontinuation of raptiva therapy and did not demonstrate tolerance induction.

vid sådana omständigheter ska raptivabehandlingen avslutas.
in such circumstances, raptiva should be discontinued.